Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Cellmark Q3 Revenues Slide 7 Percent

NEW YORK (GenomeWeb News) – Orchid Cellmark reported on Monday a 7 percent decline year over year in third-quarter revenues.

In its quarterly earnings report filed with the US Securities and Exchange Commission, the company, which is in the process of being acquired by Laboratory Corporation of America for $85.4 million, said that total revenues for the three months ended Sept. 30 slid to $16.1 million from $17.3 million in the comparable year-ago period.

Virtually all of its revenues come from its service business while other revenues dropped to $8,000, down from $13,000 a year ago.

The Princeton, NJ-based firm cut R&D expenses 3 percent to $335,000 from $344,000 a year ago, and decreased SG&A spending 6 percent to $4.7 million from $5 million.

Net loss for the quarter doubled to $1.3 million, or $.04 per share, from $665,000, or $.02 per share a year ago.

Today, LabCorp announced it had extended it cash tender offer for Orchid Cellmark to Nov. 30.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more